Thiruvanantha Puram Today

Fibrodysplasia Ossificans Progressiva Market: Epidemiology Insights, Pipeline Products, and Key Companies Working in the Market | Companies – Ipsen, Regeneron Pharmaceuticals, Ipsen, BioCryst

 Breaking News
  • No posts were found

Fibrodysplasia Ossificans Progressiva Market: Epidemiology Insights, Pipeline Products, and Key Companies Working in the Market | Companies – Ipsen, Regeneron Pharmaceuticals, Ipsen, BioCryst

September 05
21:15 2023
Fibrodysplasia Ossificans Progressiva Market: Epidemiology Insights, Pipeline Products, and Key Companies Working in the Market | Companies - Ipsen, Regeneron Pharmaceuticals, Ipsen, BioCryst
Fibrodysplasia Ossificans Progressiva Market
DelveInsight’s “Fibrodysplasia Ossificans Progressiva (FOP) Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Fibrodysplasia Ossificans Progressiva (FOP), historical and forecasted epidemiology as well as the Fibrodysplasia Ossificans Progressiva (FOP) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Fibrodysplasia Ossificans Progressiva – Market Insights, Epidemiology, and Market Forecast-2032”.

Some of the key facts of the Fibrodysplasia Ossificans Progressiva Market Report:

  • According to the European Conference on Rare Diseases, FOP has a prevalence rate of 0.08 per 100,000 people.
  • As per Delveinsight’s analysis, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in the seven major markets was found to be 630 in 2017. In the United States, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) was found to be 293 in 2017.
  •  In EU5 countries, the total diagnosed prevalent cases of Fibrodysplasia Ossificans Progressiva (FOP), in 2017, were found to be maximum in Germany with 62 cases followed by France with 50 cases, while the least number of diagnosed prevalent cases of Fibrodysplasia Ossificans Progressiva (FOP) was found in Spain with 35 cases, in 2017.
  •  As per the analysis of Delveinsight, the total diagnosed prevalent population of Fibrodysplasia Ossificans Progressiva (FOP) in Japan was found to be 95, in 2017. 

Key benefits of the report:

  1. Fibrodysplasia Ossificans Progressiva market report covers a descriptive overview and comprehensive insight of the Fibrodysplasia Ossificans Progressiva Epidemiology and Fibrodysplasia Ossificans Progressiva  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Fibrodysplasia Ossificans Progressiva market report provides insights on the current and emerging therapies.
  3. Fibrodysplasia Ossificans Progressiva market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Fibrodysplasia Ossificans Progressiva market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fibrodysplasia Ossificans Progressiva market.

Got queries? Click here to learn more about the Fibrodysplasia Ossificans Progressiva Market Landscape.

Fibrodysplasia Ossificans Progressiva Overview

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside the skeleton (extra-skeletal or heterotopic bone) that constrains movement. This process generally becomes noticeable in early childhood, starting with the neck and shoulders, and proceeding down the body and into the limbs.

Mutations in the ACVR1 gene cause fibrodysplasia ossificans progressiva. The underlying genetic mutation in FOP alters the signals that regulate the induction of cell differentiation leading to bone formation.

Fibrodysplasia Ossificans Progressiva Market 

The dynamics of the Fibrodysplasia Ossificans Progressiva market are anticipated to change in the coming years owing to the expected launch of emerging therapies by key companies such as Ipsen, Regeneron Pharmaceuticals, Ipsen, BioCryst, Keros Therapeutics, and others during the forecasted period 2019-2032.

Fibrodysplasia Ossificans Progressiva Pipeline Therapies and Key Companies 

  • Palovarotene: Ipsen
  • Garetosmab (REGN2477): Regeneron Pharmaceuticals
  • BLU-782: Ipsen
  • BCX9250: BioCryst
  • KER-047: Keros Therapeutics
  • And others

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Fibrodysplasia Ossificans Progressiva Patient Share (%) Overview at a Glance

5. Fibrodysplasia Ossificans Progressiva Market Overview at a Glance

6. Fibrodysplasia Ossificans Progressiva Disease Background and Overview

7. Fibrodysplasia Ossificans Progressiva Epidemiology and Patient Population

8. Country-Specific Patient Population of Fibrodysplasia Ossificans Progressiva 

9. Fibrodysplasia Ossificans Progressiva Current Treatment and Medical Practices

10. Unmet Needs

11. Fibrodysplasia Ossificans Progressiva Emerging Therapies

12. Fibrodysplasia Ossificans Progressiva Market Outlook

13. Country-Wise Fibrodysplasia Ossificans Progressiva Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Fibrodysplasia Ossificans Progressiva Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Fibrodysplasia Ossificans Progressiva Market Outlook 2032.

Related Reports:

Fibrodysplasia Ossificans Progressiva Pipeline Insights 2023

Fibrodysplasia Ossificans Progressiva Epidemiology Forecast 2032

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles